Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. [electronic resource]
Producer: 20090915Description: 4076-81 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Erlotinib Hydrochloride
- Feasibility Studies
- Female
- Humans
- Kaplan-Meier Estimate
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoadjuvant Therapy
- Nephrectomy
- Proportional Hazards Models
- Prospective Studies
- Quinazolines -- administration & dosage
- Risk Assessment
- Time Factors
- Treatment Outcome
- Wound Healing -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.